Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
Lynparza fails to improve on Keytruda in first-line lung cancer
Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer.
Angus Liu
Dec 7, 2023 9:21am
FDA clears Bristol Myers cancer drug from Turning Point buy
Nov 16, 2023 11:10am
AstraZeneca suffers setback in ambitious 2030 lung cancer goal
Nov 14, 2023 11:05am
Merck-Daiichi, Kelun, AstraZeneca—Fierce Pharma Asia
Oct 27, 2023 9:10am
ESMO: Should AZ worry about J&J's Tagrisso head-to-head win?
Oct 23, 2023 10:30am
ESMO: BMS' Opdivo delivers competitive perioperative NSCLC data
Oct 21, 2023 10:30am
